Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial.
Demmelmaier I, Brooke HL, Henriksson A, Mazzoni AS, Bjørke ACH, Igelström H, Ax AK, Sjövall K, Hellbom M, Pingel R, Lindman H, Johansson S, Velikova G, Raastad T, Buffart LM, Åsenlöf P, Aaronson NK, Glimelius B, Nygren P, Johansson B, Börjeson S, Berntsen S, Nordin K. Demmelmaier I, et al. Among authors: lindman h. Scand J Med Sci Sports. 2021 May;31(5):1144-1159. doi: 10.1111/sms.13930. Epub 2021 Mar 2. Scand J Med Sci Sports. 2021. PMID: 33527488 Free article. Clinical Trial.
Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study.
Acs B, Hartman J, Sönmez D, Lindman H, Johansson ALV, Fredriksson I. Acs B, et al. Among authors: lindman h. Lancet Reg Health Eur. 2024 Mar 19;40:100886. doi: 10.1016/j.lanepe.2024.100886. eCollection 2024 May. Lancet Reg Health Eur. 2024. PMID: 38745990 Free PMC article.
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.
Zhu Y, Zerdes I, Matikas A, Cruz IR, Bergqvist M, Elinder E, Bosch A, Lindman H, Einbeigi Z, Andersson A, Carlsson L, Dreifaldt AC, Isaksson-Friman E, Hellstrom M, Johansson H, Wang K, Bergh JCS, Hatschek T, Foukakis T. Zhu Y, et al. Among authors: lindman h. Breast Cancer Res Treat. 2024 Apr;204(2):299-308. doi: 10.1007/s10549-023-07200-x. Epub 2024 Jan 4. Breast Cancer Res Treat. 2024. PMID: 38175448 Free PMC article. Clinical Trial.
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project.
Cazzaniga ME, Ciaccio A, Danesi R, Duhoux FP, Girmenia C, Zaman K, Lindman H, Luppi F, Mavroudis D, Paris I, Olubukola A, Samreen A, Schem C, Singer C, Snegovoy A. Cazzaniga ME, et al. Among authors: lindman h. Front Oncol. 2023 Oct 26;13:1247270. doi: 10.3389/fonc.2023.1247270. eCollection 2023. Front Oncol. 2023. PMID: 37954071 Free PMC article.
105 results